The dualistic role of the purinergic P2Y12-receptor in an in vivo model of Parkinson's disease: Signalling pathway and novel therapeutic targets.
Animals
Brain
/ metabolism
Cell Line
Disease Models, Animal
Dopamine
/ metabolism
Humans
Male
Mice, Inbred C57BL
Mice, Knockout
Parkinsonian Disorders
/ metabolism
Purinergic P2Y Receptor Antagonists
/ pharmacology
Receptors, Purinergic P2Y12
/ genetics
Signal Transduction
p38 Mitogen-Activated Protein Kinases
/ metabolism
rho-Associated Kinases
/ metabolism
G-protein coupled receptor
Microglia
NeurodegenerationNeuroinflammation
P2Y(12)-receptor
Parkinson's disease
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
25
10
2021
revised:
09
12
2021
accepted:
23
12
2021
pubmed:
31
12
2021
medline:
22
3
2022
entrez:
30
12
2021
Statut:
ppublish
Résumé
Parkinson's disease (PD) is a chronic, progressive neurodegenerative condition; characterized with the degeneration of the nigrostriatal dopaminergic pathway and neuroinflammation. During PD progression, microglia, the resident immune cells in the central nervous system (CNS) display altered activity, but their role in maintaining PD development has remained unclear to date. The purinergic P2Y
Identifiants
pubmed: 34968684
pii: S1043-6618(21)00629-0
doi: 10.1016/j.phrs.2021.106045
pii:
doi:
Substances chimiques
Purinergic P2Y Receptor Antagonists
0
Receptors, Purinergic P2Y12
0
rho-Associated Kinases
EC 2.7.11.1
p38 Mitogen-Activated Protein Kinases
EC 2.7.11.24
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106045Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.